Holen Sie sich die Stockscreener-App
0.9794
2.06%
-0.0206
Handel nachbörslich:
1.00
0.0206
+2.10%
Schlusskurs vom Vortag:
$1.00
Offen:
$1
24-Stunden-Volumen:
150.31K
Relative Volume:
0.48
Marktkapitalisierung:
$16.05M
Einnahmen:
$19.91M
Nettoeinkommen (Verlust:
$-127.11M
KGV:
-0.1162
EPS:
-8.428
Netto-Cashflow:
$-132.44M
1W Leistung:
-11.77%
1M Leistung:
-21.02%
6M Leistung:
-81.80%
1J Leistung:
-81.66%
1-Tages-Spanne:
$0.92
$1.01
1-Wochen-Bereich:
$0.92
$1.1382
52-Wochen-Spanne:
$0.92
$8.95
Affimed N V Stock (AFMD) Company Profile
Vergleichen Sie AFMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AFMD
Affimed N V
|
0.9794 | 16.05M | 19.91M | -127.11M | -132.44M | -8.428 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Affimed N V Stock (AFMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-10-10 | Herabstufung | Stifel | Buy → Hold |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-10-21 | Eingeleitet | Truist | Buy |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2019-03-28 | Eingeleitet | SVB Leerink | Outperform |
| 2018-08-28 | Hochstufung | Jefferies | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Buy |
| 2016-08-12 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-05-19 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2015-12-10 | Eingeleitet | Laidlaw | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-09-09 | Eingeleitet | Jefferies | Hold |
| 2015-08-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-06-22 | Bestätigt | Jefferies | Buy |
Alle ansehen
Affimed N V Aktie (AFMD) Neueste Nachrichten
Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why - Defense World
Jane Street Group LLC Acquires New Position in Affimed (NASDAQ:AFMD) - Defense World
Affimed (NASDAQ:AFMD) Sees Large Increase in Short Interest - Defense World
HC Wainwright Issues Positive Forecast for Affimed Earnings - Defense World
Equities Analysts Offer Predictions for Affimed Q1 Earnings - Defense World
Affimed Shares Fall 32% on Clinical Update - GuruFocus.com
Affimed stock plunges 23% on AFM24 study update - MSN
Affimed (NASDAQ:AFMD) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Affimed stock plunges 23% on AFM24 study update (AFMD:NASDAQ) - Seeking Alpha
Affimed’s Promising Clinical Update on NSCLC Treatment - TipRanks
Affimed Reports Positive Clinical Update on - GlobeNewswire
Affimed's AFM24 Trial Shows Promising 24% Response Rate in EGFR-Mutant Lung Cancer Patients - StockTitan
Affimed says 86% of patients responded to lymphoma therapy in mid-stage trial - MSN
Wells Fargo & Company Lowers Affimed (NASDAQ:AFMD) Price Target to $15.00 - Defense World
Affimed (NASDAQ:AFMD) Short Interest Update - Defense World
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy - MSN
Affimed Reports Promising Phase 1 Efficacy and Safety Data - GlobeNewswire
Affimed Reports Promising Phase 1 Efficacy and Safety - One News Page
Affimed to Host Investor Conference Call Highlighting - GlobeNewswire
Affimed to Present AFM24 Lung Cancer Clinical Data in Conference Call - StockTitan
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial - StockTitan
Affimed Announces Positive Results Demonstrating Safety and - GlobeNewswire
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares - StockTitan
FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy - Yahoo Finance
Affimed Announces Acimtamig and AlloNK® Combination Granted - GlobeNewswire
Affimed's Cancer Therapy Wins FDA RMAT Status After Striking 83% Response Rate in Lymphoma Trial - StockTitan
Affimed Q3 2024 Earnings Preview - MSN
Is Affimed N.V. (AFMD) the Best German Stock to Buy Now? - Insider Monkey
10 Best German Stocks To Buy Now - Insider Monkey
Affimed's (AFMD) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Stifel Nicolaus Lowers Affimed (NASDAQ:AFMD) Price Target to $4.00 - Defense World
Affimed N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Stifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00 - MarketBeat
Earnings call: Affimed reports promising results and strategic focus - Investing.com
Affimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call Transcript - Insider Monkey
Affimed's (AFMD) Buy Rating Reiterated at HC Wainwright - MarketBeat
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... - Yahoo Finance
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating F - GuruFocus.com
Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ... By GuruFocus - Investing.com Canada
Affimed Reports Q3 2024 Financial Results and Updates - TipRanks
Affimed N.V.: Q3 Earnings Snapshot - Houston Chronicle
Affimed NV earnings missed by €0.09, revenue fell short of estimates - Investing.com Canada
Affimed Faces Growing Losses Amid Financial Struggles - TipRanks
Affimed Reports Third Quarter 2024 Financial Results & Business Update - The Manila Times
Finanzdaten der Affimed N V-Aktie (AFMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):